Incretin-based therapies

Pfeiffer, Prof. A. F. H., Berlin, Germany / Vora, Prof. J., Liverpool, United Kingdom / Khunti, Prof. K., Leicester, United Kingdom / Fioretto, Prof. P., Padova, Italy / Hadjadj, Dr. S., Poitiers, France / Mannucci, Dr. E., Florence, Italy / Schumm-Draeger, Prof. P.-M., Munich, Germany / Baggio, L., Canada
Interactive session & panel discussion
Mannucci, Dr. E., Florence, Italy
What can we learn from retrospective cardiovascular outcome studies?
Schumm-Draeger, Prof. P.-M., Munich, Germany
Introducing SAVOR, a prospective cardiovascular outcomes study
Vora, Prof. J., Liverpool, United Kingdom
The clinical profile of incretin-based therapies
Gallwitz, Prof. J. B., Tuebingen, Germany
Linagliptin: a new alternative in DPP-4 inhibition
Fonseca, MD V., New Orleans, United States
DPP-4 inhibitors: raising expectations
Cooper, Dr. M., Melbourne, Australia
Is the kidney the ignored heart of type 2 diabetes?
Ritzel, PD Dr. R., Munich, Germany
Visceral adipositas: strategies to counteract
Marx, Prof. N., Ulm, Germany
Potentials for cardioprotection
Holst, Prof. J. J., Copenhagen, Denmark
Going beyond conventional therapies: an update on DPP-4 inhibition
Barnett, Prof. A., Birmingham, United Kingdom
A different DPP-4 inhibitor
Ceriello, Prof. A., Barcelona, Spain
New clinical challenges and new opportunities: recent developments in type 2 diabetes in perspective
Jacob, Prof. S., Villlingen-Schwenningen, Germany
Saxagliptin: now and beyond
Del Prato, Prof. S., Pisa, Italy
Overcoming barriers now in successful treatment of type 2 diabetes
Groop, Prof. P.-H., Helsinki, Finland
Impact of declining renal function on treatment choice in diabetes
Aronson, Dr. R., Toronto, Canada
Setting a course for the future
Del Prato, Prof. S., Pisa, Italy
Why we should be treating to succeed
de Pablos, Prof. Pedro, Gran Canaria, Spain
A review of treatment satisfaction and quality of life in people with type 2 diabetes
Holst, Prof. J. J., Copenhagen, Denmark
Latest insights on incretin-based treatments
Ceriello, Prof. A., Barcelona, Spain
Reducing daily glucose peaks and valleys for comprehensive glycaemic control: a clinical perspective
Jacob, Prof. S., Villlingen-Schwenningen, Germany
New data on the emerging role of saxagliptin in type 2 diabetes
Tschöpe, Prof. D., Bad Oeynhausen, Germany
CV benefits of GLP-1 analogues and DPP-IV inhibitors: Fact or myth?
Bailey, Prof. C., Birmingham, United Kingdom
The overall burden of type 2 diabetes(Archiv)
29-Sep-09
Holst, Prof. J. J., Copenhagen, Denmark
Scientific rationale for DPP-4 inhibition(Archiv)
29-Sep-09
Rosenstock, MD J., Dallas, United States
Clinical overview of saxagliptin(Archiv)
29-Sep-09
Barnett, Prof. A., Birmingham, United Kingdom
Achieving targets safely: role of DPP-4 inhibitors(Archiv)
29-Sep-09
Barnett, Prof. A., Birmingham, United Kingdom / Charbonnel, Prof. B., Nantes, France / Bornstein, Prof. S., Dresden, Germany / Bosi, Prof. E., Milan, Italy
The place of DPP-4 inhibitors in national guidelines – country-specific perspectives(Archiv)
29-Sep-09
Holst, Prof. J. J., Copenhagen, Denmark
The Incretin Effect in Health and Disease(Archiv)
07-Sep-08
Holst, Prof. J. J., Copenhagen, Denmark
The potential of incretin enhancers in the treatment of type 2 diabetes(Archiv)
11-Sep-05
Cherrington, Prof. A., United States
The importance of glucagon in glycaemic control: emerging evidence from incretin-based intervention(Archiv)
11-Sep-05
Hughes, Prof. T. E., United States
Pancreatic islet preservation: vildagliptin (LAF237), a novel incretin enhancer, increases ß-cell function and mass in animal models(Archiv)
11-Sep-05
Ahrén, Prof. B., Sweden
Review of safety and efficacy of vildagliptin (LAF237)(Archiv)
11-Sep-05
Zimmet, Prof. P., Mellbourne, Australia
Early intervention and treatment of impaired glucose metabolism: The mounting evidence(Archiv)
11-Sep-05
Holst, Prof. J. J., Copenhagen, Denmark
Islet Dysfunction in Type 2 Diabetes – The Role of Incretin Hormones(Archiv)
13-Apr-05
Standl, Prof. E., Munich, Germany
Incretin Enhancement in Type 2 Diabetes – A Vision(Archiv)
13-Apr-05
Pi-Sunyer, Prof. X., New York, United States
Obesity: the role of incretin mimetics in the treatment of Type 2 diabetes(Archiv)
05-Sep-04
Nauck, Prof. M. A., Bad Lauterberg, Germany
Incretin overview: effects of GLP-1(Archiv)
05-Sep-04